2022 Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study Group Chronic Malignancies Working Party (CMWP) Transplant Complications Working Party (TCWP) 1st listed author Anna Waszczuk-Gajda Journal J Clin Med.
2022 Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis Group Chronic Malignancies Working Party (CMWP) 1st listed author Marie Robin Journal Blood.
2022 Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis Group Chronic Malignancies Working Party (CMWP) 1st listed author Bhagirathbhai Dholaria Journal Br J Haematol.
2022 Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Donal P McLornan Journal Br J Haematol.
2022 Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP Group Chronic Malignancies Working Party (CMWP) 1st listed author Francesco Onida Journal Bone Marrow Transplant.
2022 Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Edouard Forcade Journal Bone Marrow Transplant.
2022 Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019 Group Chronic Malignancies Working Party (CMWP) 1st listed author Dawn Swan Journal Br J Haematol.
2022 Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Joanna Drozd-Sokołowska Journal Bone Marrow Transplant.
2022 Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Laure Vincent Journal Bone Marrow Transplant.
2022 Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Nicola Polverelli Journal Lancet Haematol.
2022 Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Joanna Drozd-Sokolowska Journal Bone Marrow Transplant.
2022 Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Carmelo Gurnari Journal Bone Marrow Transplant.